OTTMUSG00000016703 Inhibitors
The inhibition of the protein LOC329436, also known as Gm14461, can be achieved through a variety of chemical compounds that target specific cellular processes and signaling pathways. These inhibitors act either directly on the protein itself or indirectly through mechanisms that disrupt its function within the cell. One approach involves the use of compounds such as Gefitinib and Staurosporine, which, although not directly related to LOC329436, possess the ability to influence downstream signaling pathways that have implications for the protein's activity. Gefitinib, for instance, is a tyrosine kinase inhibitor that primarily targets the epidermal growth factor receptor (EGFR). While its primary function is to inhibit EGFR, the downstream effects of this inhibition can indirectly affect LOC329436 due to its involvement in various cellular processes influenced by EGFR signaling. Similarly, Staurosporine, a broad-spectrum protein kinase inhibitor, can indirectly impact LOC329436 by targeting multiple protein kinases, thus potentially influencing signaling pathways associated with the protein's function.
Another strategy for inhibiting LOC329436 involves compounds like Actinomycin D and Cycloheximide, which act indirectly by disrupting the transcription and translation processes. Actinomycin D, a potent inhibitor of RNA synthesis, binds to DNA and interferes with transcription, leading to a reduction in LOC329436 mRNA levels and subsequently inhibiting its protein expression. Likewise, Cycloheximide functions as a translation inhibitor, preventing the synthesis of new protein molecules, including LOC329436. This results in decreased protein levels and functional inhibition of LOC329436's cellular activities. These compounds demonstrate that inhibition of LOC329436 can be achieved through targeted interference with critical cellular processes, ultimately affecting its function within the cell.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Gefitinib | 184475-35-2 | sc-202166 sc-202166A sc-202166B sc-202166C | 100 mg 250 mg 1 g 5 g | $63.00 $114.00 $218.00 $349.00 | 74 | |
Gefitinib is a potent tyrosine kinase inhibitor that specifically targets the epidermal growth factor receptor (EGFR). Although not directly related to the protein Gm14461, it indirectly inhibits downstream signaling pathways that may influence the function of Gm14461 due to its involvement in various cellular processes. | ||||||
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $153.00 $396.00 | 113 | |
Staurosporine is a broad-spectrum protein kinase inhibitor. While it does not directly target Gm14461, its inhibitory action on various protein kinases can indirectly affect signaling pathways associated with Gm14461, potentially leading to functional inhibition. | ||||||
Actinomycin D | 50-76-0 | sc-200906 sc-200906A sc-200906B sc-200906C sc-200906D | 5 mg 25 mg 100 mg 1 g 10 g | $74.00 $243.00 $731.00 $2572.00 $21848.00 | 53 | |
Actinomycin D is a potent inhibitor of RNA synthesis by binding to DNA. It can indirectly inhibit Gm14461 by disrupting the transcriptional machinery, leading to reduced protein expression. This results in functional inhibition of Gm14461's activity. | ||||||
Cycloheximide | 66-81-9 | sc-3508B sc-3508 sc-3508A | 100 mg 1 g 5 g | $41.00 $84.00 $275.00 | 127 | |
Cycloheximide is a translation inhibitor that can indirectly inhibit Gm14461 by preventing the synthesis of new protein molecules, including Gm14461. This leads to a decrease in Gm14461 levels and functional inhibition of its cellular functions. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $67.00 $223.00 $425.00 | 97 | |
Wortmannin is a phosphoinositide 3-kinase (PI3K) inhibitor. While not directly targeting Gm14461, it indirectly inhibits Gm14461's involvement in the PI3K signaling pathway, potentially leading to functional inhibition of Gm14461's effects in this pathway. | ||||||
MG-132 [Z-Leu- Leu-Leu-CHO] | 133407-82-6 | sc-201270 sc-201270A sc-201270B | 5 mg 25 mg 100 mg | $60.00 $265.00 $1000.00 | 163 | |
MG-132 is a proteasome inhibitor that can indirectly inhibit Gm14461 by preventing its proteasomal degradation. This leads to an accumulation of Gm14461 protein, potentially causing functional inhibition due to protein misregulation. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $63.00 $158.00 $326.00 | 233 | |
Rapamycin is an mTOR inhibitor that indirectly influences cellular processes related to Gm14461. By targeting mTOR, it can disrupt signaling pathways and cellular processes downstream of mTOR, indirectly inhibiting Gm14461's function. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $64.00 $246.00 | 136 | |
U0126 is a MEK1/2 inhibitor that can indirectly inhibit Gm14461 through its impact on the MAPK/ERK signaling pathway. It interferes with upstream kinases in the pathway, potentially leading to functional inhibition of Gm14461's effects in this pathway. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor that indirectly affects Gm14461 by disrupting the PI3K signaling pathway. By inhibiting upstream kinases in this pathway, it can lead to functional inhibition of Gm14461's effects in the context of PI3K-related processes. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor that indirectly affects Gm14461 by targeting the p38 MAPK signaling pathway. By inhibiting this pathway upstream, it can lead to functional inhibition of Gm14461's effects within the context of p38 MAPK-related processes. | ||||||